We explore what oncologists expect from ASCO 2026, with a focus on breakthrough clinical data in areas like ADCs, immunotherapy, and targeted therapies. This report also identifies a shift toward outcomes-driven sessions and more focused, high-value engagement across hybrid formats.
This Market Signal report highlights how oncologists are prioritizing breakthrough clinical data and meaningful outcomes as they head into ASCO 2026. Insights from the study show strong interest in areas like antibody-drug conjugates, immunotherapy, and targeted therapies, with a clear preference for sessions that demonstrate real impact on standard of care and patient outcomes. The report also reveals a shift toward more focused, high-value engagement, with hybrid formats and targeted interactions shaping how clinicians plan to connect and learn at the conference.
Download our ebook, “The Evolution of Market Research in Healthcare,” to discover the trends redefining the field and how Konovo is helping companies turn insight into action.
